Peapod Lane Capital LLC acquired a new position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR – Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 479,323 shares of the medical instruments supplier’s stock, valued at approximately $1,730,000. OraSure Technologies makes up approximately 1.7% of Peapod Lane Capital LLC’s portfolio, making the stock its 24th biggest holding. Peapod Lane Capital LLC owned 0.64% of OraSure Technologies as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in OSUR. Atom Investors LP bought a new position in OraSure Technologies in the 3rd quarter valued at $49,000. Creative Planning acquired a new stake in shares of OraSure Technologies in the 3rd quarter valued at $54,000. Intech Investment Management LLC acquired a new position in OraSure Technologies during the 3rd quarter valued at about $84,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in OraSure Technologies by 78.2% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 28,731 shares of the medical instruments supplier’s stock valued at $123,000 after buying an additional 12,604 shares during the period. Finally, Ballentine Partners LLC acquired a new stake in shares of OraSure Technologies during the third quarter worth $159,000. 93.50% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Separately, StockNews.com lowered OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday.
OraSure Technologies Stock Performance
Shares of NASDAQ OSUR opened at $3.74 on Thursday. OraSure Technologies, Inc. has a 52-week low of $3.52 and a 52-week high of $8.04. The stock has a market cap of $278.97 million, a P/E ratio of 24.93 and a beta of 0.05. The firm has a 50 day moving average price of $3.81 and a 200 day moving average price of $4.05.
About OraSure Technologies
OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
Recommended Stories
- Five stocks we like better than OraSure Technologies
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial
- Why Are These Companies Considered Blue Chips?
- Double-Digit Gains Ahead? These 2 Cybersecurity Stocks Look Ready
- Financial Services Stocks Investing
- Will Falling Bond Yields Send These 2 Small Caps Soaring?
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR – Free Report).
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
